Establishment of personalized medicine for NMO utilizing 11C-acetate PET

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K09339
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Neurology
• Research Institution: University of Toyama (2016-2017); Osaka University (2015)
• Principal Investigator: Nakatsuji Yuji 富山大学, 附属病院, 教授 (20332744)
• Co-Investigator(Kenkyū-buntansha): 奥野 龍禎 大阪大学, 医学系研究科, 助教 (00464248) ; 甲田 亨 大阪大学, 医学部附属病院, 医員 (70626134) ; 南波 明子 大阪大学, 医学部附属病院, 医員 (80774504) ; 山下 和哉 大阪大学, 医学部附属病院, 医員 (40774518)
• Project Period (FY): 2015-10-21 – 2018-03-31
• Keywords: PET / 酢酸 / アストロサイト / 多発性硬化症 / NMO / バイオマーカー

Outline of Final Research Achievements

To distinguish NMO and MS is clinically important because the prophylactic treatments are different for each disease. We have been working to establish 11C-acetate PET as a novel imaging biomarker to distinguish those two diseases. Ten healthy controls, 11 MS patients, and 12 NMOSD patients were enrolled, and we found that astrocytic metabolism is activated in the brain with MS, while it is decreased in the brain with NMO. Thus, it is expected that we can utilize 11C-acetate PET as a novel imaging biomarker for the differential diagnosis of MS and NMOSD.

Free Research Field

神経免疫学